Date: January 12, 2021
Duration: 47 Minutes
Monitoring the status of the immune system is critical in immunotherapy clinical trials. Measuring the levels of specific cell types can provide information to understand mode of action, help profile responders vs. non-responders, or characterize the status of tumor tissue.
In this webinar, Uli Hoffmueller, Ph.D., of Precision for Medicine, will share data on how immune monitoring by the epigenetic technology Epiontis ID can solve common challenges in measuring key cell types in immuno-oncology trials, with a case study in a checkpoint inhibitor, anti-TIGIT antibody therapeutic.
Topics covered:
-
Key immune cell types in checkpoint inhibitor trials, and the correlation of specific cell type ratios with overall outcomes
-
Differences between immune monitoring methods such as IHC, flow cytometry, and epigenetic immune monitoring, and the advantages of each
-
How to effectively incorporate immune monitoring via Epiontis ID into immuno-oncology trials to enrich trial data and to ease logistical and planning challenges
